Filgotinib for the treatment of rheumatoid arthritis
Introduction: Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy. Being proteins, they are administered parenterally. The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme fa...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Published: |
Taylor and Francis
2017
|